

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Pten-/- Spry2+/- SP1

RRID:CVCL_VQ86

Type: Cell Line

Proper Citation

RRID:CVCL_VQ86

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_VQ86

Proper Citation: RRID:CVCL_VQ86

Description: Cell line Pten-/- Spry2+/- SP1 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Carcinoma of the mouse prostate gland

Comments: Miscellaneous: Cell line information from personal communication of Patel, Rachana., Characteristics: Tumorigenic in immunocompromised mice (CD-1 nudes) as prostate orthografts., Characteristics: From a primary prostate tumour from a Ptenpcfl/fl Spry2fl/+ mice (Probasin Cre driven Pten deletion and Spry2 heterozygous loss in murine prostate epithelium).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Pten-/- Spry2+/- SP1

Synonyms: SP1

Cross References: Wikidata:Q98128703

ID: CVCL_VQ86

Record Creation Time: 20220427T221445+0000

Record Last Update: 20260905T182144+0000

Ratings and Alerts

No rating or validation information has been found for Pten-/- Spry2+/- SP1.

No alerts have been found for Pten-/- Spry2+/- SP1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Rushworth LK, et al. (2020) Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British journal of cancer, 122(4), 517.

Rushworth LK, et al. (2020) In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer. Life science alliance, 3(12).